Clinical Trial Update: Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating VX-950 (telaprevir) in combination with pegylated interferon alfa-2a, with or without ribavirin (Copegus) for chronic hepatitis C; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• VX-950 (Telaprevir)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2011-07-21